Trial · NCT01705106
Adverse events86
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 86
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Treatment (Capecitabine, Celecoxib) | 5 | 21 | |
| other | Agitation | Psychiatric disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Anal hemorrhage | Gastrointestinal disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Capecitabine, Celecoxib) | 9 | 21 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Blood bilirubin increased, intermittent (Gilbert's syndrome) | Investigations | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Bullous dermatitis (on heels from treadmill) | Skin and subcutaneous tissue disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Cataract, right eye | Eye disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Constipation | Gastrointestinal disorders | Treatment (Capecitabine, Celecoxib) | 2 | 21 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment (Capecitabine, Celecoxib) | 3 | 21 | |
| other | Creatinine increased | Investigations | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Capecitabine, Celecoxib) | 11 | 21 | |
| other | Dizziness | Nervous system disorders | Treatment (Capecitabine, Celecoxib) | 2 | 21 | |
| other | Dry skin, palms | Skin and subcutaneous tissue disorders | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Dysgeusia | Nervous system disorders | Treatment (Capecitabine, Celecoxib) | 3 | 21 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Treatment (Capecitabine, Celecoxib) | 7 | 21 | |
| other | Eye infection, left eye staph infection | Infections and infestations | Treatment (Capecitabine, Celecoxib) | 1 | 21 | |
| other | Fall | Injury, poisoning and procedural complications | Treatment (Capecitabine, Celecoxib) | 1 | 21 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01705106/events